Chip-based gene technology increasingly tying diagnostic, pharmaceutical development -- SB's Leschly.
This article was originally published in The Gray Sheet
Executive Summary
CHIP-BASED GENETIC TECHNOLOGY's LINKAGE OF DIAGNOSTIC AND DRUG DEVELOPMENT activities will become apparent over the next several years as commercial applications of genomics -- the study of gene location, structure and function -- are brought to bear through increased collaboration among the medical device, biotechnology and pharmaceutical industries, according to SmithKline Beecham Chief Executive Jan Leschly.You may also be interested in...
EU Preserves Status Quo On Drugs Under Additional Monitoring
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
Meitheal Gets US Enoxaparin Approval
Through its partnership with majority stakeholder Nanjing King-Friend Biochemical Pharmaceutical, Meitheal Pharmaceuticals has received FDA approval for enoxaparin, a generic rival to Lovenox.
EU Approvals: Evenity Cleared For Severe Osteoporosis
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: